Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.

Leukemia·2017
Same author

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma.

Blood cancer journal·2017
Same author

Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia.

Blood cancer journal·2017
Same author

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.

Leukemia·2016
Same author

Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 30, 2026

Non-invasive Optical Imaging of the Lymphatic Vasculature of a Mouse
09:52

Non-invasive Optical Imaging of the Lymphatic Vasculature of a Mouse

Published on: March 8, 2013

Imaging guiding therapy development in lymphoma.

B K Link1

  • 1Holden Comprehensive Cancer Center, Division of Hematology Oncology, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA. brian-link@uiowa.edu

Clinical Pharmacology and Therapeutics
|September 20, 2008
PubMed
Summary
This summary is machine-generated.

Radiographic imaging is a traditional measure of lymphoma therapy success. While new treatments may challenge this standard, innovative imaging techniques can still guide future lymphoma drug development.

More Related Videos

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

Related Experiment Videos

Last Updated: Jun 30, 2026

Non-invasive Optical Imaging of the Lymphatic Vasculature of a Mouse
09:52

Non-invasive Optical Imaging of the Lymphatic Vasculature of a Mouse

Published on: March 8, 2013

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

Area of Science:

  • Oncology
  • Radiology
  • Medical Imaging

Background:

  • Radiographic imaging has historically served as a key surrogate for treatment efficacy in lymphoma therapy development.
  • Nodal lymphomas are typically measurable in two dimensions and often show prompt shrinkage with effective therapies, indicating long-term clinical benefit.

Purpose of the Study:

  • To discuss the established role of radiographic imaging in lymphoma therapy development.
  • To explore the challenges posed by emerging therapeutic strategies to the traditional imaging paradigm.
  • To highlight the potential of creative imaging approaches in guiding future lymphoma treatment development.

Main Methods:

  • Review of historical and current practices in radiographic assessment for lymphoma.
  • Analysis of the paradigm of radiographic response as a benchmark for new therapies.
  • Discussion of the impact of novel therapeutic strategies on imaging-based decision-making.

Main Results:

  • Radiographic response has been a long-standing requirement for new lymphoma therapies, dating back to early imaging methods and Hodgkin's lymphoma (HL).
  • Current therapeutic strategies in lymphoma still rely on inducing radiographic response.
  • New therapeutic strategies are emerging that may challenge the traditional reliance on radiographic assessment.

Conclusions:

  • The established paradigm of using radiographic imaging to guide lymphoma therapy development is deeply rooted.
  • While new therapeutic strategies may challenge this paradigm, creative imaging approaches remain crucial for guiding future development.
  • Innovative imaging solutions are needed to adapt to and support the evolution of lymphoma treatment strategies.